Hutchison China Meditech Ltd (HCM)
HCM Share PerformanceMore
|52 week high||3,335.75 20/03/17|
|52 week low||1,670.00 29/04/16|
|52 week change||1,242.50 (72.03%)|
|4 week volume||237,825 04/04/17|
Latest News« previous» nextMore
28/04/2017 - 13:40 RNS
RNS Number: 7219D Hutchison China Meditech Limited 28 April 2017 Total Voting Rights London: Friday , April 28, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at April 28, 2017, the issued share capital of Chi-Med consisted of 60,735,104 ordinary shares of US$1.00 each, with...
27/04/2017 - 14:10 RNS
RNS Number: 5842D Hutchison China Meditech Limited 27 April 2017 Results of Annual General Meeting London: Thursday, April 27, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) today announces that all ordinary resolutions and special resolutions put to its Annual General Meeting ("AGM") held on April 27, 2017 were duly passed. T...
13/04/2017 - 14:33 Interactive Investor
This portfolio has returned 275% since 2010; David Brenchley finds out which potential "money-making machine" has mo...
07/04/2017 - 07:43 StockMarketWire
Hutchison China MediTech presented pre-clinical data for fruquintinib and sulfatinib at the American Association for Ca...
07/04/2017 - 07:00 RNS
RNS Number: 8957B Hutchison China Meditech Limited 07 April 2017 Press Release Chi-Med Presented Pre-clinical Data for Fruquintinib and Sulfatinib at the American Association for Cancer Research Annual Meeting 2017 London: Friday, April 7, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) presented pre-clinical data for fruquintin...
31/03/2017 - 07:00 RNS
RNS Number: 1321B Hutchison China Meditech Limited 31 March 2017 Total Voting Rights London: Friday , March 31, 2017: For information purposes, Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) hereby notifies the market that as at March 31, 2017, the issued share capital of Chi-Med consisted of 60,715,323 ordinary shares of US$1.00 each, wi...
29/03/2017 - 09:45 StockMarketWire
Christian Hogg, Chief Executive Officer, has transferred in 5,620 shares in the company on the 28th March 2017 at a price...
29/03/2017 - 08:07 RNS
RNS Number: 8508A Hutchison China Meditech Limited 29 March 2017 Vesting of awards under the Long Term Incentive Plan London: Wednesday, March 29, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) announces that following the publication of the 2016 annual report of Chi-Med on March 27, 2017, the following awards granted u...
Equity Research (HCM)
Hutchison China MediTech Limited
Hutchison (HCM) and partner Lilly announced positive, top-line pivotal phase III trial results for fruquintinib in 3rd line colorectal cancer. The China based FRESCO study evaluating 416 patients who...
Hutchison China MediTech Limited
Hutchison (HCM) and partner AstraZeneca presented positive preliminary data from the ongoing phase II proof-of-concept trial evaluating savolitinib (c-Met TKI) in papillary renal cell carcinoma (PRCC...
Hutchison China MediTech Ltd.
Chi-Med’s CEO, Christian Hogg, delivered a confident and convincing presentation at the recent interim analyst meeting. It was certainly refreshing to hear a CEO explain a drop in profits (and doing...
- 1 of 3
Latest discussion posts More
“Figured you'd come back and confirm as such. Excellent, thank you.”▼
“Yes I did, I have been invested and continue to build a substantial holding since 2008 and it was my 4th AGM. I met the Chief Executive again and it was also a pleasure to ...”▼
“Did you go mate, what did you think/learn? Thanks”▼
Codes & Symbols
|Symbols||HCM, LSE:HCM, HCM.L, HCM:LN, LON:HCM, XLON:HCM|